Navigation Links
Allscripts Announces Convertibility of its Outstanding 3.50 Percent Senior Debentures
Date:6/10/2009

CHICAGO, June 10 /PRNewswire-FirstCall/ -- Allscripts announced today that its 3.50 percent Convertible Senior Debentures due 2024 (the "Debentures") are now convertible at the option of the holders of the Debentures and will remain convertible during the fiscal quarter ending August 31, 2009. Any determinations regarding the convertibility of the Debentures during future periods will be made in accordance with the terms of the indenture under which the Debentures were issued (the "Indenture").

The Debentures became convertible because the last reported sale price of Allscripts common stock for at least 20 consecutive trading days within the 30-trading-day period ending on May 29, 2009 was greater than 130 percent of the conversion price in effect on May 29, 2009. As a result, during the conversion period, holders of the Debentures may convert the Debentures into shares of common stock, subject to the terms of the Indenture. Pursuant to the terms of the Indenture, the Debentures are convertible at the conversion rate of 124.3781 shares per $1,000 principal amount of each Debenture. Allscripts has the right to satisfy the conversion with cash in lieu of shares of common stock in accordance with the terms of the Indenture.

Additionally, Allscripts announced today that, pursuant to the terms of the Indenture, holders of Debentures have the right to require Allscripts to repurchase their Debentures (the "Repurchase Right") for cash in an amount equal to 100 percent of the principal amount of the Debentures ($1,000 per each $1,000 principal amount outstanding) plus accrued and unpaid interest and Liquidated Damages (as defined in the Indenture) to, but excluding, July 15, 2009. The Repurchase Right is subject to the terms and conditions described in the Notice of Right to Require Repurchase sent to Debenture holders and the Indenture. The Repurchase Right will expire at 5:00 p.m., Eastern Daylight Time, on July 15, 2009.


'/>"/>
SOURCE Allscripts
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Allscripts and SYNNEX Corporation Form Distribution Partnership to Accelerate Adoption of Electronic Health Records
2. Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record
3. JDRF Illinois Names Allscripts CEO Glen Tullman Best of Illinois for His Efforts to Find a Cure for Type 1 Diabetes
4. Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care
5. Cardinal Health to Offer Allscripts Electronic Health Record to Solo and Small Physician Groups
6. Edge Health to Offer Allscripts MyWay(TM) for Mac(R) Electronic Health Record
7. Allscripts Ranked No. 1 in Electronic Prescription Routing for Second Consecutive Year
8. Allscripts Announces Final Tax Treatment of Special Cash Dividend From the Transactions With Misys plc Completed in October 2008
9. Allscripts Integrates Electronic Health Record With Innovative Patient Kiosk
10. Allscripts Integrates Electronic Health Records with Innovative Patient Kiosk
11. Allscripts Introduces SaaS Solution for Prenatal Care

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., KELOWNA, BC, Nov. 27 /PRNewswire/ - Uploadabl...eeing prime time in wellness. A combination of adv...ta upload are solving a long term concern over the... to accurately gauge and reward improved participa...logies is one of the first wellness suppliers to i...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCall/...unced that Blair Lambert, CFO/COO, will present at...be held at the May Fair Hotel in London, England, ... ,, To listen to a live broadcast of The Gymbor...lease log on to www.gymboree.com, click on "Our Co...
(Date:11/27/2009)..., KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-F... SHMR ) ( "Shamir" ), a leading provider of innov...ns market, announced today that its board of direc...gregate amount of US$ 10 million (approximately NI...resentative rate of exchange), or approximately US...
(Date:11/27/2009)...g rates to bring unprecedented medical, economic b...27 (HealthDay News) -- The number of people with d... over the next 25 years, a new study predicts. ,... million people with the disease, up from 23.7 mil...eating people with diabetes will triple, the study...
(Date:11/27/2009)... Multi-purpose bilingual colori...ned for use by the business community to educate -... subjects from Safety issues to Dinosuars to ABC,S... Saint Louis, MO (PRWEB) November 27, 2009 --...ronics or toys to keep them busy any hour of the d...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2
...ASPS Twins Study Finds Environmental Factors Trump...Ill., Feb. 3 Your mother,s wrinkles -- or lack th...l age. In fact, a new study claims just the opposi...ge. Results just published on the web-based versio...
...CORTLANDT MANOR, N.Y., Feb. 3 Polymedco is please...to colorectal cancer statistics and screening. It...ns to risks, statistics, and screening options for...ay in the United States. However, with proper scr...
... FORT WORTH, Texas, Feb. 3 Galderma Laboratori...ug Administration (FDA) has approved,Vectical(TM) ...product for the,treatment of mild-to-moderate plaq...ed, scaly patches of skin and,caused by an abnorma...
...Event to Benefit The Larry King Cardiac Foundation...th Annual Red Dress Awards will commemorate Americ...iduals who have made significant contributions to ... Jazz at Lincoln Center,s Allen Room. The View ...
... MIAMI, Feb. 3 Baker & McKenzie, and Banks...009 Summit aimed at informing investors,in the hea...February 12th at,the Harvard Club. , Internati...Center of Miami and Palm Beach, Florida,( http://w...
...CHICAGO, Feb. 3 The Female Health Company (NYSE A...n investor conference call to discuss its operatin... a.m. Eastern Time (EST) on Tuesday, February 10, ...cipate in the conference call by dialing 800-860-2...
Other Medicine News:Health News:Divorce, Antidepressants, or Weight Gain/Loss Can Add Years to Your Face 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 3Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 4Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 2Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 3Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 4Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 5Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 6Health News:James G. Schwade, M.D. to Deliver Keynote Address to Financial and Investment Industry in New York 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2
(Date:11/25/2009)... -- BioTrends Research Group, Inc. released Wave 1...the first in a multi-phase syndicated market resea...Biotech,s Stelara, from product launch through the...he report provides quantitative information from 7...n from a subset of 20. The reports assess trial a...
(Date:11/25/2009)... For many of the millions...million living with untreated hearing loss , the ...st Cindy Beyer. ,, Dr. Beyer, senior vice presi...rgest hearing care and hearing aids companies, s...ustration, and social isolation, "which can easily...
(Date:11/25/2009)...PRNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a s... APFC ) announced today that it received the Envi...at the Annual Statewide Environmental Summit, spon...gy Association (CMTA), the Industrial Environmenta...cil of California (CICC) held in San Diego. This ...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Cruise Ship Virus Vaccine Stems From Tobacco 54758 1Cruise Ship Virus Vaccine Stems From Tobacco 54758 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 1PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 3Bankrupt Medicare to be Burdened With 24Billions More for Translation Costs Says ProEnglish 54750 1
...presented at the 90th annual Endocrine Society mee...ected by moderate to severe vaginal ...Mich, June 16 QuatRx Pharmaceuticals today,announ...al Phase 3 clinical,trial of Ophena(TM) (ospemifen...toms of vulvovaginal atrophy, a common condition a...
...lished in the Journal of the American Society of H...giotensin II reversed vascular ... A new study published in the,current Journal of t...hat,the hypertension treatment olmesartan medoxomi...arteries that occurs in patients with hypertension...
Other Medicine Technology:Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 2New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 3New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 5New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 6New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 7New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 8New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 9
Long Handle Occluder - White
Long Handle Occluder - Black
49 Pinhole short handle
Red Maddox and Red lens
Medicine Products: